Mehta Kunal, Moravcikova Erika, McFall David, Luketich James D, Pennathur Arjun, Donnenberg Albert D, Donnenberg Vera S
Department of Cardiothoracic Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Department of Cardiothoracic Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Ann Thorac Surg. 2017 Jul;104(1):321-328. doi: 10.1016/j.athoracsur.2017.01.091. Epub 2017 May 9.
The epithelial-mesenchymal transition (EMT) is thought to contribute to the overall invasiveness of malignant cells. Expression of cluster of differentiation (CD) 44 and CD90 mark the mesenchymal state in multiple epithelial malignancies. Their role in lung cancer remains unclear, however. This study evaluated the prognostic significance of CD44 and CD90 coexpression in patients with resectable primary non-small cell lung cancer (NSCLC).
This was a nonconcurrent cohort study of patients with resectable NSCLC, stratified by the degree of expression of CD44/CD90 double-positive cells in their primary tumor. Flow cytometry was used for immunophenotyping of freshly isolated disaggregated tumor. We analyzed the relationship between expression of CD44/CD90 and relapse-free survival.
We evaluated 37 patients (18 men; median age, 70 years) with NSCLC. For this group, the geometric mean proportion of cells coexpressing CD44/CD90 was 0.52%. Expression of CD44/CD90 was significantly elevated (24.4%, geometric mean) in 6 patients. The median relapse-free survival for patients with high CD44/CD90 coexpression was 7.7 months (95% confidence interval, 4.2 to 11.7) compared with 40 months (95% confidence interval, 18.2 to 77.8) for the group with low CD44/CD90 coexpression (p = 0.00006 by Mantel log-rank test). The assessment of risk based upon CD44/CD90 expression status was not correlated with pathologic staging (p = 0.073 by χ).
High expression of CD44 and CD90 was associated with significantly reduced relapse-free survival in NSCLC patients. These results suggest that CD44 and CD90 may be important markers of tumor progression in NSCLC.
上皮-间质转化（EMT）被认为与恶性细胞的整体侵袭性有关。分化簇（CD）44和CD90的表达标志着多种上皮性恶性肿瘤中的间质状态。然而，它们在肺癌中的作用仍不清楚。本研究评估了CD44和CD90共表达在可切除的原发性非小细胞肺癌（NSCLC）患者中的预后意义。
这是一项对可切除NSCLC患者的非同期队列研究，根据其原发性肿瘤中CD44/CD90双阳性细胞的表达程度进行分层。流式细胞术用于对新鲜分离的解离肿瘤进行免疫表型分析。我们分析了CD44/CD90表达与无复发生存率之间的关系。
我们评估了37例NSCLC患者（18例男性；中位年龄70岁）。对于该组患者，共表达CD44/CD90的细胞几何平均比例为0.52%。6例患者中CD44/CD90的表达显著升高（几何平均为24.4%）。CD44/CD90共表达高的患者中位无复发生存期为7.7个月（95%置信区间，4.2至11.7），而CD44/CD90共表达低的组为40个月（95%置信区间，18.2至77.8）（Mantel对数秩检验，p = 0.00006）。基于CD44/CD90表达状态的风险评估与病理分期无关（χ检验，p = 0.073）。
CD44和CD90的高表达与NSCLC患者无复发生存率显著降低相关。这些结果表明，CD44和CD90可能是NSCLC肿瘤进展的重要标志物。
